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Abstract Rifampicin is an antibacterial drug which is
highly effective in the treatment of tuberculosis and lep-
rosy. It has been shown to exert antioxidative as well as
anti-apoptotic effects. In this study, the neuroprotective
effect of rifampicin was examined after 1-methyl-4-phenyl-
pyridinium (MPP+)-induced dopaminergic cell death in
vitro, and on the survival of retinal ganglion cells after op-
tic nerve transection in vivo. Rifampicin administration
significantly increased the number of surviving dopami-
nergic neurons after MPP+ intoxication as compared to
control cultures. No cytotoxic effects were noted even at
final rifampicin concentrations of 100 µM. In the rifampicin-
treated group, retinal ganglion cell survival was signifi-
cantly increased after axotomy as compared with vehicle-
treated and phosphate-buffered saline-treated control ani-
mals. These results suggest that rifampicin is able to pre-
vent neuronal degeneration in cell death paradigms in-
volving oxidative stress and activation of apoptotic path-
ways. It may thus play a role in the future treatments of
neurodegenerative disorders.
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Introduction
The most effective treatment for leprosy is the multi-drug
therapy recommended by the World Health Organization
consisting of dapsone, clofozamine and rifampicin [20]. It
was recently reported that non-demented elderly leprosy
patients showed an unusual absence of senile plaques in
their brains compared with age-matched controls [15]. This
report surmised that some drug being used for leprosy
treatment might be neuroprotective. Rifampicin is a semi-
synthetic derivative of the rifampycins, a class of broad-
spectrum antibiotics that are fermentation products of No-
cardia meditterranei. It reaches maximal serum concen-
trations 1–4 h after application and its plasma half time is
2–5 h [1]. The common structure of rifampycins is a naph-
thohydroquinone or naphthoquinone chromophore spanned
by an aliphatic ansa chain [18]. This lipophilic ansa chain
is mainly responsible for the transport of the drug across
the blood-brain/retina barriers [14]. The structural feature
of its naphthohydroquinone ring suggested that rifampicin
may function as a hydroxyl radical scavenger, and it was
shown to inhibit β-amyloid (Aβ) aggregation and Aβ-in-
duced neurotoxicity [15]. Neuroprotective actions of free
radical scavengers in neurodegenerative disorders have
been well established [7].
In this study we evaluated putative neuroprotective ef-
fects of rifampicin on the survival of cultured dopaminer-
gic (DAergic) neurons in the 1-methyl-4-phenylpyridinium
(MPP+)-lesion paradigm in vitro and retinal ganglion cells
(RGCs) after transection of the optic nerve (ON) in vivo.
Material and methods
Primary ventral midbrain floor culture
The mesencephalon floor was dissected from embryonic day 14
Wistar rats and further processed for establishing dissociated cell
cultures as previously described [13]. In brief, tissue pieces were
collected in ice-cold calcium-magnesium-free balanced salt solu-
tion and centrifuged at 1,000 rpm for 4 min. The tissue pellet was
incubated in 750 µl trypsin (0.25%, 15 min, 37°C; Sigma). Trypsin
was inactivated by addition of 750 µl cold fetal calf serum. The
pellet was dissociated by gentle trituration using a fire-polished
Pasteur pipette. After centrifugation at 1,000 rpm for 4 min, the
pellet was resuspended in warm culture medium. Cells were seeded
in poly-L-ornithine/laminin (Sigma)-coated 96-well culture plates
(Nunc) at a density of 175,000 cells/cm2. Cultures were maintained
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at 37°C in a humidified atmosphere and 5% CO2 in DMEM/F12
plus the N1 supplements and antibiotics for 4 or 7 days. Medium
was changed on days in vitro (DIV) 1 and 3. Cultures were virtu-
ally free of glial fibrillary acidic protein-positive astroglial cells
throughout the culture period [12, 13]. Rifampicin (Sigma) was
added on DIV 4 at concentrations of 0.1, 1, 10 or 100 mM. 3 h af-
ter rifampicin application MPP+ (Sigma) was added to the culture
at a final concentration of 4 µM. Cells were fixed 24 h after MPP+
application with 4% formaldehyde and immunocytochemically
stained for tyrosine hydroxylase (TH) as previously described
[13]. Numbers of TH-positive cells were counted in approximately
10% of the culture area in each well (n=4) using a fluorescence mi-
croscope (Axioplan; Zeiss, Germany).
Animal groups and RGC labeling technique
All experimental procedures were carried out according to the Na-
tional Institutes of Health guidelines for the care and use of labo-
ratory animals with permission of local government authorities.
Adult male C57BL/6J mice (Charles River Laboratory, Sulzfeld,
Germany), weighing 22–25 g, were assigned to the following ex-
periments and groups: (a) phosphate-buffered saline (PBS)-treated
group (n=3); (b) vehicle-treated group (n=6); (c) rifampicin-
treated group (n=7). All retinas were prepared 14 days following
ON axotomy. RGCs were retrogradely labeled prior to ON tran-
section. Animals were anesthetized by i.p. injection of 7% chloral hy-
drate. The superior colliculi were exposed by drilling a bur hole into
the pericranium 0.7 mm lateral to the sagittal suture and 3.0 mm
posterior to bregma. A Hamilton syringe was inserted 2.0 mm be-
neath the surface of the brain, and 0.750 µl Fluorogold (FG, Fluo-
rochrom, LLC, Denver, CO; infusion rate 0.7 µl/min) were injected
stereotactically into both superior colliculi. After infusion, the nee-
dle remained inside the tissue for 2 min to prevent FG diffusion
along the needle track, before the syringe was withdrawn, and the
wound closed with a suture [10].
ON axotomy and administration of rifampicin
Four days after labeling, mice were anesthetized by i.p. injection
of 7% chloral hydrate. After skin incision close to the superior or-
bital rim, the right orbita was opened, leaving the supraorbital vein
intact, and the lacrimal gland was resected subtotally. After
spreading the superior extraocular muscles, the right ON was tran-
sected under microscopical control approximately 0.5 mm distant
to the posterior pole of the eye, taking care not to damage the reti-
nal blood vessels. The wounds were sutured and the retinal blood
supply was verified by fundoscopy [10].
Rifampicin (Sigma Chemicals, St Louis, MO) was dissolved in
ethanol and further diluted in normal saline to a final concentration
of 13%. A rifampicin bolus of 5 mg/kg body weight was injected i.p.
just after axotomy. Two micro-osmotic pumps (Alzet, Palo Alto,
CA; model 1002) were placed into the abdominal cavity after ON
transection. During the subsequent 14 days, rifampicin (5 mg/kg
body weight per day) was continuously applied i.p. with the micro-
osmotic pump at a flow rate of 0.5 µl/h.
Tissue processing
At 14 days after ON transection, the mice were killed by an over-
dose of chloral hydrate and both eyes were removed. The retinas
were dissected, fixed in 4% paraformaldehyde (PFA) in 0.1 M PBS
for 30 min and flat-mounted on glass slides. Survival of RGCs was
evaluated by fluorescence microscopy using a rhodamine filter
(546/590 nm). RGC densities were determined by counting tracer-
labeled RGCs in 12 distinct areas of 62,500 µm2 each (three areas
per retinal quadrant at three different retinal eccentricities of 1/6,
3/6 and 5/6 of the retinal radius, respectively) [5]. Only those cells
were counted that were clearly detectable as RGCs because of their
size and morphology. The RGCs were round, and cell bodies were
bigger than those of microglial cells, which were FG-positive to
some extent because of phagocytosis.
Statistics
For statistical data comparisons, a standard software package
(SPSS for Windows) was used. Differences between groups in the in
vivo experiments were measured by repeated measures ANOVA.
Differences between groups in the in vitro experiments were cal-
culated by unpaired t-tests. All values are given as mean ± SD.
P values less than 0.05 are considered significant.
Results
Effects of rifampicin on survival of DAergic neurons 
in vitro
Treatment of midbrain cultures with rifampicin did not af-
fect survival of DAergic neurons in a statistically signifi-
cant manner as compared to the non-rifampicin-treated
group. Most importantly, no toxic effect of rifampicin was
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Fig. 1 Rifampicin at concentrations of 100, 10 and 1 µM inhibits
MPP+-induced dopaminergic cell death. Numbers of surviving
TH-positive neurons are significantly increased as compared to the
non-rifampicin-treated controls. *P≤0.05. Data are given as mean
± SD
Fig. 2 RGCs surviving 14 days after ON transection, given as
fractions of cell numbers in non-axotomized eyes. Areas were
counted separately at one-sixth, one-half, and five-sixths of the
retinal radius as indicated. *Significant difference (P<0.05) com-
pared with PBS-treated control animals. $Significant difference
(P<0.05) compared with vehicle-treated control animals. Data are
given as mean ± SD (RGC retinal ganglion cell, ON optic nerve)
noted up to a final concentration of 100 µM (Fig. 1; con-
trol group).
MPP+ administration to midbrain cultures resulted in a
reduction of surviving DAergic neurons to approximately
62–70% of control values, in the 0.1 µM and 0 µM ri-
fampicin-treated groups, respectively. Rifampicin at con-
centrations of 1, 10 and 100 µM significantly increased
the number of surviving DAergic neurons as compared to
the non-rifampicin-treated controls. DAergic cell numbers
could be restored to up to 88–99% of the control values
(Fig. 1; MPP+ group).
Effects of rifampicin on survival of RGCs in vivo
Cell counts of FG-labeled RGCs from axotomized ani-
mals are summarized in Fig. 2 and Table 1. Rifampicin
treatment significantly increased the number of surviving
RGCs as compared to vehicle-treated or PBS-treated ani-
mals. The effect of rifampicin, vehicle-treated control and
PBS-treated control on the density of RGCs are shown in
Fig. 3. The number of viable cells in the rifampicin-treated
animals was significantly increased as compared with
PBS-treated control and vehicle treated animals (Fig. 3). The
number of viable cells in the vehicle-treated animals was
also increased as compared with PBS-treated control ani-
mals. However, this neuroprotection was not at a signifi-
cant level. Rifampicin rescued 1.5–2 times more RGCs at
1/6, 3/6 and 5/6 of the retinal radius than control injec-
tions (Table 1; Fig. 2).
Discussion
In the present study, we evaluated the neuroprotective ef-
fects of rifampicin on DAergic neuron and RGC survival in
a combined in vitro and in vivo approach using the MPP+
intoxication and ON axotomy models. After rifampicin
administration, cell numbers of TH-labeled DAergic neu-
rons and of FG-labeled RGCs were significantly increased.
Oxidative stress has been shown to play a major role in
the pathophysiology of neurodegeneration in both experi-
mental models employed in our study. MPP+ is the active
metabolite of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyri-
dine (MPTP); in vivo MPTP is metabolized to MPP+ by
astroglial cells and then taken up into DAergic neurons by
the dopamine transporter [16]. MPP+ exerts its neurotoxic
actions by inhibition of the complex I activity of the re-
spiratory chain as well as induction of lipid peroxidation.
MPP+-induced cell death is also associated with activation
of apoptotic cascade elements, e.g., the JNK pathway, p53-,
Bax-signaling and caspase activation [4]. Antioxidative
agents, e.g., U-78517F and deprenyl, and radical scav-
engers, e.g., DMSO, have previously been shown to be
protective against MPP+-induced neuron damage [21].
Transection of the ON triggers a highly coordinated re-
sponse of injury-associated genes, which finally leads to
apoptosis of RGCs [8, 11]. There is evidence to suggest
that free oxygen radicals enhance injury programs. Free
oxygen radicals are highly reactive molecules that contain
one or more unpaired electrons. Under normal physiolog-
ical conditions, antioxidant defense mechanisms are pre-
sent to combat reactive oxygen radicals. In neurodegener-
ative disease, production of reactive oxygen species over-
whelms endogenous scavenging mechanisms and is able
to damage lipids, proteins, nucleic acids and carbohy-
drates. Antioxidant agents suppress apoptosis induced by
various insults, including axotomy [3].
The free radical-scavenger activity of rifampicin has al-
ready been shown by electron spin resonance spectromet-
ric analysis and stable free radical, alpha, alpha-diphenyl-
beta-picrylhydrazyl (DPPH) reduction [9, 15]. Next to the
antioxidative properties of rifampicin, several other mech-
anisms have been discussed as being neuroprotective: re-
cent studies showed that rifampicin binds to and activates
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Table 1 Surviving RGCs in
different eccentricities of the
retina in unlesioned control and
axotomized eyes. Data are
given as mean RGC densites
(cells/mm2) ± SD at one-sixth,
one-half and five-sixths of the
retinal radius of the retinal ra-
dius and averaged over the ra-
dius (RGC retinal ganglion cell)
1/6 retinal 1/6 retinal 1/6 retinal Average
radius radius radius
Rifampicin (unlesioned) 3,805±811 3,084±856 2,362±564 3,084±747
Rifampicin (axotomy) 2,165±560 1,948±311 1,647±386 1,920±292
Vehicle (unlesioned) 3,534±672 3,100±494 1,976±469 3,105±545
Vehicle (axotomy) 1,809±452 1,512±408 938±259 1,512±316
Control (unlesioned) 3,320±626 2,980±948 2,260±268 3,245±614
Control (axotomy) 1,078±110 1,055± 78 985±224 1,182± 72
Fig. 3 Effects of rifampicin on the RGCs surviving 14 days after
ON transection. Note that the number of viable RGCs was signifi-
cantly increased in rifampicin-treated mice as compared with con-
trol animals. *Significant difference (P<0.05) compared with PBS-
treated control animals. $Significant difference (P<0.05) compared
with vehicle-treated control animals. Data are given as mean ± SD
glucocorticoid receptors (GRs), resulting in the induction
of transcription of genes controlled by glucocorticoid re-
ceptor-binding elements [2]. GRs were shown in isolated
Müller and photoreceptor cells in intact salamander retina
and in all cell types in the human eye [17]. Activated GRs
can inhibit AP-1, which in turn is essential for the induc-
tion of photoreceptor apoptosis by light. GR-mediated in-
hibition may occur in the nucleus of retinal cells by a pro-
tein-protein interaction of both transcription factors. Thus,
induction of GR activity prevents light–induced retinal de-
generation by interference with AP-1-dependent steps of
apoptosis induction in mice [19]. Gollapudi et al. [6] re-
ported that rifampicin-mediated inhibition of apoptosis and
activation of caspase-3 and capase-8 occurred at least in
part via GR activation. Furthermore, rifampicin down-
regulated the expression of pro-apoptotic Bax and up-reg-
ulated the expression of anti-apoptotic Bcl-2, Bcl-XL and of
anti-apoptotic gene products such as XIAP, cIAP2, FLIPs,
which play essential roles to block programmed cell death.
Rifampicin is a well-established and generally well-
tolerated drug for the treatment of tuberculosis and lep-
rosy. Our present data underline the pathophysiological
significance of the neuroprotective mechanisms of this
compound. Rifampicin may, therefore, play a beneficial
neuroprotective role in the future treatment of neurode-
generative diseases, such as Parkinson’s disease.
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